Neuroleptics and dopamine transporters

被引:25
作者
Reader, TA [1 ]
Ase, AR [1 ]
Huang, N [1 ]
Hébert, C [1 ]
van Gelder, NM [1 ]
机构
[1] Univ Montreal, Fac Med, Dept Physiol, Ctr Rech Sci Neurol, Montreal, PQ H3C 3J7, Canada
基金
英国医学研究理事会;
关键词
haloperidol; clozapine; raclopride; SCH23390; dopamine uptake sites;
D O I
10.1023/A:1022405621365
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The effects of neuroleptic treatments on dopamine transporters and on dopamine receptors was investigated in the forebrain of adult rats treated for 21 days with either haloperidol, clozapine or saline. The dopamine D-1 receptors, labeled with [H-3]SCH23390, increased in nucleus accumbens, latero-dorsal rostral neostriatum and substantia nigra, after clozapine but not haloperidol. The dopamine D-2 receptors, studied with [SH]raclopride, increased in nucleus accumbens and in dorsolateral, ventro-medial and dorso-medial quadrants of the rostral neostriatum after either haloperidol or clozapine treatments, and also in latero-ventral rostral neostriatum but only after haloperidol. Haloperidol also up-regulated D-2 receptors in rostral and caudal neostriatum, but clozapine produced a more uneven increase, especially in caudal neostriatum. In contrast, the densities of dopamine uptake sites, or transporters, labeled with [I-125]RTI-121, remained unchanged after both neuroleptic treatments. The observation that dopamine transporters are resistant to treatments that modify D-1 and D-2 receptors indicates that these uptake sites can probably be ruled out as the target of neuroleptic drugs, and that dopamine receptor up-regulations can indeed occur independently of the densities of nerve endings at the terminal fields of innervation.
引用
收藏
页码:73 / 80
页数:8
相关论文
共 40 条
[1]   CHANGES IN CATALEPSY AND RECEPTOR SENSITIVITY FOLLOWING CHRONIC NEUROLEPTIC TREATMENT [J].
ALLIKMETS, LH ;
ZARKOVSKY, AM ;
NURK, AM .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1981, 75 (2-3) :145-147
[2]   NEUROTRANSMITTER TRANSPORTERS - RECENT PROGRESS [J].
AMARA, SG ;
KUHAR, MJ .
ANNUAL REVIEW OF NEUROSCIENCE, 1993, 16 :73-93
[3]  
BARLOW RB, 1983, BIODATA HANDLING MIC
[4]  
BOJA JW, 1995, MOL PHARMACOL, V47, P779
[5]  
BOYSON SJ, 1986, J NEUROSCI, V6, P3177
[6]  
CARLI M, 1997, IN PRESS BIOCH PHARM
[7]   RISPERIDONE AND CLOZAPINE IN THE TREATMENT OF DRUG-RESISTANT SCHIZOPHRENIA AND NEUROLEPTIC-INDUCED SUPERSENSITIVITY PSYCHOSIS [J].
CHOUINARD, G ;
VAINER, JL ;
BELANGER, MC ;
TURNIER, L ;
BEAUDRY, P ;
ROY, JY ;
MILLER, R .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1994, 18 (07) :1129-1141
[8]  
CRISWELL H, 1989, J NEUROSCI, V9, P125
[9]   D-1 DOPAMINE-RECEPTORS IN THE RAT-BRAIN - AUTORADIOGRAPHIC LOCALIZATION USING [H-3]SCH 23390 [J].
DAWSON, TM ;
GEHLERT, DR ;
YAMAMURA, HI ;
BARNETT, A ;
WAMSLEY, JK .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1985, 108 (03) :323-325
[10]   ARE ANTAGONISTS OF DOPAMINE-D1 RECEPTORS DRUGS THAT ATTENUATE BOTH POSITIVE AND NEGATIVE SYMPTOMS OF SCHIZOPHRENIA - A PILOT-STUDY IN JAVA']JAVA MONKEYS [J].
ELLENBROEK, BA ;
WILLEMEN, APM ;
COOLS, AR .
NEUROPSYCHOPHARMACOLOGY, 1989, 2 (03) :191-199